TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12106618
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (88 microg, twice daily for 6 weeks)
Study: 12106618
Drug: Zafirlukast (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zafirlukast (20 mg, twice daily for 6 weeks)
Study: 28542868
Drug: 15 ml
Normalized name: ethanol 0.15 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 ml lidocaine 2%
Study: 28542868
Drug: 15 ml
Normalized name: ethanol 0.15 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 ml saline
Study: 21585062
Drug: Acu-moxibustion treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acu-moxibustion treatment (12 weeks, once every other day, main acupoints: Feishu, Geshu, Ganshu, Pishu, Shenshu; moxibustion applied for about 3 min each time)
Study: 21585062
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (oral Acitretin capsules, 20 mg/d for 12 weeks)
Study: 19175613
Drug: Non-specific treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-specific treatment
Study: 14742356
Drug: Aprotinin regimen
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprotinin regimen with a bolus of 1 x 10(6) kallikrein inhibiting units (KIU) before CPB, 1 x 10(6) KIU in the priming solution, and a continuous infusion of 250,000 KIU/h during CPB.
Study: 14742356
Drug: Heparin management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin management according to Hepcon HMS Plus.
Study: 9671343
Drug: Mirtazapine (15-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (15-60 mg/day)
Study: 11476127
Drug: Venlafaxine (75-375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (75-375 mg/day, twice a day)
Study: 9782221
Drug: Dirithromycin (D)
Normalized name: Dirithromycin
DrugBank: Dirithromycin (DB00954)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dirithromycin (D) 500 mg once daily for 5 days
Study: 8156516
Drug: High-dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cyclophosphamide (CY) 2400 mg per M2 as a single-day dose and vincristine (VCR) 1.4 mg per M2 given on Day 1 after CY
Study: 8156516
Drug: High-dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cyclophosphamide (CY) 2400 mg per M2 as a single-day dose and vincristine (VCR) 1.4 mg per M2 given on Day 9 after CY
Study: 8156516
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard doses of chemotherapy)
Study: 30762217
Drug: Arthroscopic suprapectoral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthroscopic suprapectoral intraosseous implant-free biceps tenodesis (ASIIBT) with Cobra Guide (CG)
Study: 26625506
Drug: Financial incentive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Financial incentive ($8 per medication per month)
Study: 26625506
Drug: Financial incentive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Financial incentive ($8 per medication per month) in diabetics
Study: 26625506
Drug: Financial incentive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Financial incentive ($8 per medication per month) in nondiabetics
Study: 10855738
Drug: Trandolapril (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril (2 mg)
Study: 8855526
Drug: Pulse-spray thrombolysis
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse-spray thrombolysis plus angioplasty
Study: 27502800
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium (75 mg/im)
Study: 24337978
Drug: QGC001 (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: QGC001 (10, 50, 125, 250, 500, 750, 1,000, and 1,250 mg)
Study: 22395187
Drug: Infant formula
Normalized name: Infant formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infant formula supplemented with 2.0 g/L FOS
Study: 22395187
Drug: Infant formula
Normalized name: Infant formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infant formula supplemented with 3.0 g/L FOS
Study: 16036387
Drug: Magnesium (2
Normalized name: magnesium gluconate 12.5 mg magnesium (250 mg) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium (2 g/h)
Study: 16036387
Drug: Fenoterol (270
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol (270 microg/h) + Verapamil (0.2 mg/h)
Study: 16036387
Drug: Nifedipine (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (0.25 mg/ml) in vitro
Study: 10550454
Drug: Estradiol 25
Normalized name: estradiol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol 25 mg/day
Study: 10550454
Drug: Estradiol 50
Normalized name: estradiol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol 50 mg/day
Study: 10550454
Drug: Estradiol 75
Normalized name: ESTRADIOL 75MCG/DAY (VIVELLE-DOT) PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol 75 mg/day
Study: 10550454
Drug: Estradiol (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol (all doses)
Study: 8905799
Drug: Erythromycin 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 1,200 mg/day for 10 days
Study: 6140938
Drug: ICI 118551
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 118551 20 mg
Study: 6140938
Drug: ICI 118551
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 118551 50 mg
Study: 28303364
Drug: Pomegranate juice
Normalized name: pomegranate juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate juice (500 mL daily for one week)
Study: 25209368
Drug: Phosphate binding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphate binding medication adherence intervention
Study: 21844061
Drug: Methylprednisolone sodium
Normalized name: methylPREDNISolone sodium phosphate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone sodium phosphate (1.6 mg/kg per day for 3 days)
Study: 12971032
Drug: Ketoconazole 200
Normalized name: ketoconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 200 mg as intact tablets with water
Study: 12971032
Drug: Ketoconazole 200
Normalized name: ketoconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 200 mg as tablets crushed in acidic juice
Study: 12971032
Drug: Ketoconazole 200
Normalized name: ketoconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 200 mg as intact tablets
Study: 8218758
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg each morning)
Study: 8218758
Drug: Famotidine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine (40 mg at night time)
Study: 3578422
Drug: 5000 U
Normalized name: lipase 5000 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5000 U sodium heparin
Study: 3578422
Drug: 7500 U
Normalized name: amylase 97500 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7500 U sodium heparin
Study: 3578422
Drug: 10000 U
Normalized name: papain 10000 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10000 U sodium heparin
Study: 3578422
Drug: Heparin neutralization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin neutralization activity
Study: 29125719
Drug: Obiltoxaximab 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obiltoxaximab 4 mg/kg
Study: 29125719
Drug: Obiltoxaximab 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obiltoxaximab 8 mg/kg
Study: 29125719
Drug: Obiltoxaximab 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obiltoxaximab 16 mg/kg
Study: 29125719
Drug: Obiltoxaximab 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obiltoxaximab 20 mg/kg
Study: 29125719
Drug: Obiltoxaximab 24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obiltoxaximab 24 mg/kg
Study: 29125719
Drug: Obiltoxaximab (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obiltoxaximab (all doses)
Study: 24439682
Drug: Individual cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual cognitive behavioural treatment
Study: 24439682
Drug: Group cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive behavioural treatment
Study: 24439682
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual improved with Smith's norms
Study: 23275372
Drug: Grape polyphenols
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grape polyphenols (PPs) 2 g/day
Study: 26689304
Drug: Integrative cognitive‐affective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative cognitive‐affective therapy for BN (ICAT‐BN)
Study: 27467700
Drug: Enhanced cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced cognitive behavior therapy (CBT‐E)
Study: 23000708
Drug: Calcium‐incorporated titanium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium‐incorporated titanium implants
Study: 23000708
Drug: Control titanium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control titanium implants
Study: 8718563
Drug: Cilazapril (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril (1 mg single dose at the end of HD session)
Study: 1572445
Drug: HDM injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDM injections
Study: 3917653
Drug: Bestatin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bestatin (30 mg/day) and FT‐207 (0.6 g/day p.o.) after 1/2MF'C regimen (mitomycin C 2 mg and cytosine arabinoside 20 mg i.v. twice a week for 3 weeks, FT‐207 400 mg/day i.v. for 3 weeks)
Study: 31566694
Drug: Osteopathic manipulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic manipulative treatment (OMT) plus usual obstetric care
Study: 31566694
Drug: Placebo ultrasound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ultrasound treatment plus usual obstetric care
Study: 24273968
Drug: Bushen Yijing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bushen Yijing Decoction (BYD), tamoxifen tablet (TT), Licorzine Capsule (LC), and Vitamin E Soft Capsule (VESC)
Study: 24273968
Drug: Bushen Yijing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bushen Yijing Decoction (BYD), Licorzine Capsule (LC), and Vitamin E Soft Capsule (VESC)
Study: 24273968
Drug: tamoxifen tablet
Normalized name: tamoxifen Oral Tablet
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tamoxifen tablet (TT), Licorzine Capsule (LC), and Vitamin E Soft Capsule (VESC)
Study: 24273968
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group and control group 1
Study: 16839836
Drug: 20% lipid/heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% lipid/heparin infusion at a rate of 1.5 mL/min for 6 hours
Study: 16839836
Drug: Saline/heparin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline/heparin infusion at a rate of 1.5 mL/min for 6 hours
Study: 10706957
Drug: Bicomponent acellular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicomponent acellular vaccine (pertussis toxin and filamentous hemagglutinin)
Study: 10706957
Drug: Monocomponent acellular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monocomponent acellular vaccine (pertactin)
Study: 9305674
Drug: Ribavirin combined
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin combined with alpha interferon (3 million units three times weekly for 6 months)
Study: 9529766
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen treatment
Study: 29253747
Drug: 15 mg/kg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg/d of methylprednisolone (group T1, n=17)
Study: 29253747
Drug: 15 mg/kg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg/d of methylprednisolone at consent and 100 mg/2 h until kidney harvest (group T2, n=17)
Study: 29092730
Drug: Clopidogrel generic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel generic 75 mg
Study: 29092730
Drug: Clopidogrel reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel reference 75 mg
Study: 8566257
Drug: Oral micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral micronized E2
Study: 1662191
Drug: ITRA-PEL (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITRA-PEL (2 x 100 mg once daily)
Study: 1662191
Drug: ITRA-PEG (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITRA-PEG (4 x 50 mg once daily)
Study: 6125185
Drug: Pindolol 20
Normalized name: pindolol 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol 20 mg
Study: 30520216
Drug: Whey/guar preload
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey/guar preload (150 mL containing 17 g whey protein plus 5 g guar)
Study: 24472156
Drug: Dihydroartemisinin-piperaquine (DP)
Normalized name: .alpha.-dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin-piperaquine (DP) paediatric tablets
Study: 22948132
Drug: Cabergoline 0.25mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline 0.25mg for 8 days from the day of HCG administration
Study: 20718766
Drug: r-hPRL (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-hPRL (60 μg/kg) administered subcutaneously every 12 h for 28 days (Study 1)
Study: 20718766
Drug: r-hPRL (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-hPRL (60 μg/kg) administered every 12 h for 7 days (Study 2)
Study: 20718766
Drug: r-hPRL (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-hPRL (60 μg/kg) administered daily for 7 days (Study 2)
Study: 20718766
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered for 7 days (Study 2)
Study: 17951067
Drug: 4 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g/d curcumin
Study: 17951067
Drug: 1 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/d curcumin
Study: 15664003
Drug: Menatetrenone (MK-4)
Normalized name: menatetrenone
DrugBank: Menatetrenone (DB12148)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menatetrenone (MK-4) 45 mg, ergocalciferol (vitamin D2) 1000 IU, calcium 600 mg daily for 2 years
Study: 7726651
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg gemeprost (Cergem)
Study: 2024813
Drug: Dexamethasone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.5 mg/kg/day for 3 days)
Study: 19614965
Drug: Prednisolone (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (150 mg)
Study: 14688699
Drug: Enoxaparin 1
Normalized name: ENOXAPARIN 100MG/ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 1 mg/kg twice daily (n = 21)
Study: 14688699
Drug: Intravenous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous heparin (n = 20)
Study: 8825016
Drug: Ocuguard (broad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ocuguard (broad spectrum antioxidant capsule)
Study: 28566688
Drug: Low-dose HDM
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose HDM specific sublingual immunotherapy (n = 29)
Study: 28566688
Drug: High-dose HDM
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose HDM specific sublingual immunotherapy (n = 26)
Study: 26187555
Drug: Interferon-based therapy
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-based therapy for 12 weeks
Study: 20604775
Drug: Conventional cytology
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional cytology (CC) in NETHCON
Study: 20604775
Drug: Conventional cytology
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional cytology (CC) in NTCC
Study: 16700881
Drug: Furosemide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (20 mg/day)
Study: 16700881
Drug: ACEI (imidapril
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEI (imidapril 5 mg/day)
Study: 16700881
Drug: ACEI (imidapril
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEI (imidapril 5 mg/day) + Spironolactone (25 mg/day)
Study: 16700881
Drug: ACEI (imidapril
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEI (imidapril 5 mg/day) + Furosemide (20 mg/day)
Study: 12699450
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment (Genotropin, 0.8 IU daily for 1 month, then 1.6 IU daily for 5 months)
Study: 1465036
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation alone (500 mg/day)
Study: 6146570
Drug: Long-term maintenance
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term maintenance training in patients on beta-blocker therapy
Study: 29176359
Drug: Virtual intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual intravenous simulator
Study: 22067902
Drug: Ibandronate 150
Normalized name: ibandronate 150 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate 150 mg oral monthly
Study: 18497717
Drug: Dialectical behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical behavior therapy for Substance Abusers (DBT-SAB)
Study: 11792604
Drug: Oral ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibandronate (doses: 0.25, 0.50, 1.0, 2.5, or 5.0 mg daily)
Study: 11012955
Drug: Sedation protocol
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedation protocol with rectal midazolam (0.5 mg x kg(‐1)) and S‐(+)‐ketamine (5 mg x kg(‐1)) plus i.v. supplementation (20+/‐10 microg x kg(‐1) x min(‐1) S‐(+)‐ketamine and 4+/‐2 microg x kg(‐1) x min(‐1) midazolam)
Study: 8787886
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg genaconazole (racemate)
Study: 8787886
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg or 200 mg genaconazole (RR enantiomer)
Study: 8787886
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of 14C-labeled genaconazole
Study: 1449110
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 2'-deoxycoformycin (dCF) and adenine arabinoside (ara-A)
Study: 4016828
Drug: Wax-matrix iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wax-matrix iron preparation
Study: 4016828
Drug: Sustained-release iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release iron preparation
Study: 26893170
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral melatonin
Study: 29027815
Drug: l‐carnosine (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: l‐carnosine (800 mg/day in 2 divided doses)
Study: 18160247
Drug: Other chemotherapeutic
Normalized name: Other chemotherapeutics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other chemotherapeutic agents (OC)
Study: 14628178
Drug: Flupenthixol decanoate
Normalized name: flupenthixol decanoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupenthixol decanoate (10 mg, injected every second week for 24 weeks)
Study: 14628178
Drug: Flupenthixol decanoate
Normalized name: flupenthixol decanoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupenthixol decanoate (10 mg) in male patients
Study: 14628178
Drug: Flupenthixol decanoate
Normalized name: flupenthixol decanoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupenthixol decanoate (10 mg) in female patients
Study: 7670929
Drug: Human leukocyte
Normalized name: Human leukocyte antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human leukocyte interferon-alpha (2 x 10(6) IU/g)
Study: 7670929
Drug: Podophyllotoxin 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Podophyllotoxin 0.5% in hydrophilic cream
Study: 2189027
Drug: Standard Triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Triple Therapy (Hydrochlorothiazide + Propranolol + Hydralazine)
Study: 7005629
Drug: Levamisole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole (2.5 mg/kg orally on two consecutive days each week for 26 weeks)
Study: 31082942
Drug: Cytoreductive nephrectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoreductive nephrectomy in combination with sunitinib
Study: 26134359
Drug: (1→3)‐β‐d‐glucan (BDG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (1→3)‐β‐d‐glucan (BDG) assay with cutoff positivity ≥80 pg/mL
Study: 26134359
Drug: Candida albicans
Normalized name: Candida Albicans
DrugBank: Candida albicans (DB10429)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candida albicans germ tube antibody (CAGTA) assay with cutoff positivity ≥1/160
Study: 26134359
Drug: BDG and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDG and CAGTA kinetics in IC patients treated with antifungals
Study: 26134359
Drug: Confounding factors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Confounding factors (amoxicillin–clavulanate, piperacillin–tazobactam treatments, recent surgery, Gram‐positive bloodstream infection, renal replacement therapy, enteral nutrition)
Study: 19470696
Drug: Tipifarnib 600
Normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tipifarnib 600 mg orally twice a day for the first 21 consecutive days in 28-day cycles
Study: 15209646
Drug: Acetaminophen 650
Normalized name: acetaminophen 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 650 mg four times a day (qid)
Study: 15209646
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered qid with acetaminophen as needed (prn)
Study: 2535953
Drug: Radiation plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation plus ACNU (30 mg/m2 x 4 times during irradiation)
Study: 792861
Drug: Mianserin ('Bolvidon')
DrugBank: Mianserin (DB06148)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mianserin ('Bolvidon') at an average dose of 40 mg a day
Study: 792861
Drug: Imipramine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine at an average dose of 100 mg a day
Study: 31488314
Drug: Roluperidone 32
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roluperidone 32 mg
Study: 31488314
Drug: Roluperidone 64
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roluperidone 64 mg
Study: 30886125
Drug: Inhaled nemiralisib
Normalized name: Nemiralisib
DrugBank: Nemiralisib (DB16253)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nemiralisib (0.1‐6.4 mg) for up to 14 days
Study: 30886125
Drug: Inhaled nemiralisib
Normalized name: Nemiralisib
DrugBank: Nemiralisib (DB16253)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nemiralisib (2 mg, once daily)
Study: 30886125
Drug: Inhaled nemiralisib
Normalized name: Nemiralisib
DrugBank: Nemiralisib (DB16253)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nemiralisib
Study: 30045355
Drug: Intranasal Ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal Ketamine (1 mg/kg)